Key facts
- Hemeo’s last known valuation is $65.8M (Oct 2026).
- It has raised $8.1M; the latest was Later Stage VC ($15.0M) in Oct 2026.
- Notable investors include NLC Health Ventures, Health Engine Accelerator, ScaleNL, Yahara Software.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Hemeo
- ·The full record, as it builds
Funding rounds
No funding rounds for Hemeo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hemeo
Developer of a clinical decision support platform designed for blood coagulation management. The company's platform consolidates data from multiple sources in a form that doctors can act on early and with confidence to reduce excess morbidity and death, enabling healthcare providers to improve patients' recovery process and survival rate.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2019
- Employees
- 3
- Website
- hemeo.health/
- Ownership
- Privately Held (backing)
Hemeo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hemeo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hemeo in its N-PORT filings yet. We sweep new filings monthly.